Please login to the form below
TerSera Therapeutics
This page shows the latest TerSera Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Grünenthal buys Zomig rights as AZ slimming drive continues
This work has seen it agree deals with TerSera Therapeutics ($320m for Zoladex), ProStakan ($70m for Moventig), Aspen ($770m for seven anaesthetics drugs) and, most recently, Recordati ($300m for two blood
Latest news
-
AZ agrees to $320m deal for Zoladex
TerSera Therapeutics acquires rights to oncology drug in US and Canada. ... AstraZeneca has sold the rights to its big-selling cancer drug Zoladex in Canada and the US to TerSera Therapeutics, as the UK firm moves to focus on its newer oncology
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Latest Intelligence
-
Deal Watch February 2017
In February, it granted North American rights to Zoladex, a goserelin acetate implant for prostate and breast cancer and benign gynaecological disorders, to US company TerSera Therapeutics. ... Licence. 358. AstraZeneca/ TerSera Therapeutics. Zoladex,
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Welcoming analytics-driven digital marketing agency closerlook to the Fishawack Health pack
The company works with a range of innovative biopharma companies including UCB, Novo Nordisk, Astellas, Akebia, TerSera Therapeutics, Zogenix, BioMarin, and argenx.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- NHS App to revolutionise digital health and care with major digital updates by 2023
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- The Power of AI in Medical Education
- First evidence-based guide launched to put patients at heart of digital innovations
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- New Swiss research reveals how Omicron evades the immune system
- Evoke Kyne Named Communiqué Communications Consultancy of the Year 2021
- Michael Grela Elected President of the Society for Health Communication
- Roche shares new positive Ocrevus data for MS patients
- A creative awakening – how pharma is bringing innovation to the patient journey
- European Commission approves potential new treatment for Pompe disease
- The importance of beliefs in creative health engagement
- Launch leaders’ blog part 1
- Launch leaders' blog part 2
PMHub
Page & Page and Partners
For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...
Latest intelligence
- Five big changes in the healthcare comms landscape
- The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
- Early communications in Pharma: How effective pre-approval comms delivers launch success
- What communications are required for a successful launch...
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
